Clinical trials: Insulin
Erectile Dysfunction, Metabolic Syndrome
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
This is a controlled, randomized, multi-center prospective study of vardenafil to determine efficacy on Erectile Dysfunction (ED), tolerability and safety in men with ED and Metabolic Syndrome.
- Trial name
- NCT00738400
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- 19 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes Mellitus, Type 2
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
- Trial name
- MOSAIc (NCT01400971)
- Where
- 153 sites in United States, Argentina and 17 more
- Volunteers
- 4,299 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Primary Objective: To demonstrate the non-inferiority of H0E901-U300 to Lantus, in change of glycated hemoglobin A1c (HbA1c). Secondary Objectives: To demonstrate the superiority of H0E901-U300 in comparison with Lantus in…
- Trial name
- SENIOR (NCT02320721)
- Testing
- Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy
- Where
- 162 sites in United States, Argentina and 16 more
- Volunteers
- 1,014 people
- Sponsor
- Sanofi
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled…
- Trial name
- DUAL™IV (NCT01618162)
- Testing
- insulin degludec/liraglutide
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes.
- Trial name
- SWITCH PRO (NCT03687827)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 67 sites in United States, Canada and 4 more
- Volunteers
- 498 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus.
- Trial name
- NCT00137046
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 582 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available…
- Trial name
- NCT01994746
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 8 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.
- Trial name
- NCT00511472
- Testing
- MK-0941, LANTUS insulin
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus, Pregnancy
Orchestra Pregnancy Observational Study in Poland
The aim of this project is to document the use of insulin pump therapy (CSII), including sensor augmented pump therapy (SAP), before, during and after pregnancy in women with type 1 Diabetes Mellitus benefiting from the Orchestra…
- Trial name
- NCT01779141
- Where
- 24 sites in Poland
- Volunteers
- 481 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
- Trial name
- NCT00998881
- Testing
- Teneligliptin 20 mg
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to…
- Trial name
- NCT00357370
- Testing
- Dapagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
- Trial name
- NCT01584232
- Testing
- LY2189265, Insulin glargine, Sulfonylureas (SU)
- Where
- 15 sites in Japan
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes
The Accu-Chek DiaPort system enables continuous intraperitoneal insulin infusion (CIPII): that is, infusion of insulin into the peritoneal cavity using an Accu-Chek insulin pump and an infusion set.
- Trial name
- NCT01483352
- Testing
- Accu-Chek DiaPort
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche